Search Site

Zilico Limited

9th Mar '17

EIS offers improved detection of cervical cancer

A prospective study on over 800 patients has been published in the European Journal of Obstetrics and Gynecology and Reproductive Biology.

The objective of the large-scale study was to assess the influence of high-risk Human Papilloma Virus (hrHPV) genotyping on the detection of high-grade disease (CIN2+) using colposcopic impression both with and without EIS as an adjunct.

The paper discusses the influence of high risk HPV genotype on colposcopic performance and the study demonstrates improved detection of disease with ZedScan, particularly in non-HPV 16 patients.

ZedScan detects the development of pre-cancerous abnormalities of the cervix and offers in real-time and more accurate detection of pre-cancerous cells than standard colposcopy; enabling clinicians to make better informed decisions at a patient’s first visit. 

The results of the study showed that ZedScan’s use of EIS increased the detection of CIN2+ irrespective of hrHPV genotype, particularly in non-HPV 16 patients.

ZedScan could help detect an additional 10,000 women per year with high grade disease in the UK. 

For more information about Zilico, please contact:
Zilico Ltd, tel: +44 161 826 7840; email: info@zilico.co.uk or visit www.zilico.co.uk

For press enquiries, please contact:

Julia Price, tel: +44 7737 864 878; e-mail: julia@juliaprice.co.uk